Nickan Research Institute Journal of Renal Endocrinology 2423-6438 3 1 2017 01 01 Administration of baclofen in end-stage renal disease e02 e02 EN Fatemeh Hayati Mohammad Amin Nasouti Shokhouh Shayanpour Shahla Ahmadi Halili Journal Article 2016 11 04 2016 12 19 Baclofen with chemical name of 4-amino-3-(-4-chlorophenyl)-butanoic acid is commonly used to treat dysfunctional voiding, intractable hiccups, palatal myoclonus and for alleviation of signs and symptoms of skeletal muscle spasticity and spasm. It is also currently used to treat trigeminal neuralgia, addiction to opiates, alcohol, or cocaine and for alleviation of pain among patients with multiple sclerosis or in patients with spinal or cerebral disorders. In individuals with disturbed kidney function and particularly in the patients with end-stage renal disease (ESRD), the accumulation of the drug is occurred and the half-life of the drug is prolonged which can lead to significant side effects and complication including neurological deterioration and coma.